)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nolato
Nolato (NOLA) investor relations material
Nolato Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 sales rose 7% to SEK 2,500m; organic growth was 3% excluding currency and acquisitions, which contributed SEK 56m from September 1.
Adjusted EBITA was SEK 262m versus SEK 274m, with adjusted margin at 10.5% versus 11.7%; input costs, start-up costs and customer model changes weighed on results.
Medical Solutions led growth; Engineered Solutions faced Automotive weakness and lower Hygiene volumes. Operating cash flow increased to SEK 332m, and leverage was 1.0x adjusted EBITDA.
Financial highlights
Q3 net sales were SEK 2,500m versus SEK 2,342m; 9M sales were SEK 7,311m versus SEK 7,190m.
Q3 EBITA was SEK 254m versus SEK 281m; adjusted for acquisition costs and the prior-year insurance gain, EBITA was SEK 262m versus SEK 274m.
Q3 profit after tax was SEK 172m versus SEK 215m; EPS was SEK 0.64 versus SEK 0.80.
Operating cash flow increased to SEK 332m from SEK 301m; cash flow after investments, excluding acquisitions and disposals, was SEK 141m versus SEK 118m.
Outlook and guidance
FY 2026 CapEx is expected at SEK 600m–650m, below SEK 788m in 2025.
No Q4 raw-material headwind is expected if current conditions persist; the Q2–Q3 lag effect is considered complete absent new pressures.
Medical project ramp-up costs are expected to continue for some quarters, with gradual improvement; expansion in Hungary and the US is proceeding to plan.
Automotive headwinds are expected to continue in Q4; outlook beyond Q4 remains uncertain.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nolato
- Sales up 4% organically, margins pressured by costs, strong cash flow and CEO transition.NOLA
Q2 2026 - 3% organic growth, stable margins, and strong cash flow amid challenging conditions.NOLAQ1 2026
- Q4 sales rose 2% adjusted for currency, with EBITA margin up and Medical Solutions leading growth.NOLAQ4 2025
- Q2 2025 saw 4% organic sales growth and margin gains, led by Medical Solutions and expansion.NOLAQ2 2025
- Q3 2024 delivered higher sales, margin gains, and strong cash flow despite automotive headwinds.NOLAQ3 2024
- Q2 EBITA margin hit 10.0% with strong cash flow, despite a 2% sales drop.NOLAQ2 2024
- Raised financial targets and value chain expansion drive growth and sustainability.NOLACMD 2025
- EBITA up 14% to SEK 271m, with margin gains and Medical Solutions driving growth.NOLAQ1 2025
- Q4 profit and margin surged on 5% sales growth, with strong cash flow and stable dividend.NOLAQ4 2024
Next Nolato earnings date
Q4 20268 Feb, 2027
Nolato
Next Nolato earnings date
Q4 20268 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nolato AB develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products for medical technology, pharmaceutical, consumer electronics, telecom, automotive, and other industrial sectors in North America, Sweden, Asia, and other Europe region.
The company offers medical products that include medical consumable components; pre-filled drug delivery devices; packaging solutions for pharma products comprising primary packaging solutions of injectables and solids; medtech components; transdermal skin-applied delivery systems; inflatable seals; specialized injection molded materials with specific properties; custom-molded lyo-bags; and flexible component assemblies. Nolato AB was incorporated in 1938 and is headquartered in Torekov, Sweden.